Stay updated on Reirradiation With Pembrolizumab in Head-and-Neck Clinical Trial
Sign up to get notified when there's something new on the Reirradiation With Pembrolizumab in Head-and-Neck Clinical Trial page.

Latest updates to the Reirradiation With Pembrolizumab in Head-and-Neck Clinical Trial page
- Check6 days agoNo Change Detected
- Check14 days agoChange DetectedAdded a Locations section with Maryland and Pennsylvania entries and updated the page revision to v3.3.3. Removed the Maryland Locations and Pennsylvania Locations sections and the HHS Vulnerability Disclosure link, replacing revision v3.3.2 with v3.3.3.SummaryDifference0.3%

- Check21 days agoNo Change Detected
- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedFooter revision updated to v3.3.2, replacing the previous v3.3.1.SummaryDifference0.1%

- Check42 days agoChange DetectedRevision: v3.3.1 replaces the previous v3.2.0 on the page. No substantive study details or functionality changes are indicated.SummaryDifference0.1%

- Check50 days agoChange DetectedDeleted the government funding lapse notice that was previously displayed on the page; it had directed users to cc.nih.gov and opm.gov for operating status updates.SummaryDifference0.4%

- Check64 days agoChange DetectedResults for NCT02289209 were posted on ClinicalTrials.gov on 2025-03-06, including updated outcome measures and data tables.SummaryDifference0.4%

- Check93 days agoChange DetectedMajor change: new government operating status notice and updated version to v3.2.0. Minor changes: removal of a specific resource title and old version label.SummaryDifference3%

Stay in the know with updates to Reirradiation With Pembrolizumab in Head-and-Neck Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Reirradiation With Pembrolizumab in Head-and-Neck Clinical Trial page.